MET and lung adenocarcinoma: Aberrant MET activation can be caused by several altered biological processes, but mainly two are of clinical interest in NSCLC: MET gene amplification, which is observed in 2%–4% of NSCLC, and MET exon 14 skip mutations, which have been found in 3%–4% of lung adenocarcinomas [73, 74].